SCP
ACRS icon

Sender Company & Partners’s Aclaris Therapeutics ACRS Stock Holding History

Sender Company & Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,132
Closed -$438K – 51
2021
Q4 		$438K Buy
+30,132
New +$457K 0.22% 76

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Sender Company & Partners's ACRS Position: Q1 2022 in Review

Sender Company & Partners sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 30,132 shares — an estimated $438K sold.

Sender Company & Partners first reported a position in ACRS in Q4 2021 and held it in 1 quarter. The position peaked at $438K in Q4 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Sender Company & Partners reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 30,132 Aclaris Therapeutics shares in Q1 2022, an estimated $438K.
  • Sender Company & Partners first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Aclaris Therapeutics position peaked at $438K in Q4 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.